Take Action With the Respect to any Abbreviated New Drug Application ("ANDA") Referencing Ventavis
🏛 Food and Drug Administration (FDA)FDA-2013-P-0424
Documents
2
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
OtherJul 10, 2026
Final Response Letter from FDA CDER to Actelion Pharmaceuticals Ltd.No comment period
- Other· Apr 24, 2013No comment period